World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
36071
World Ranking
16901
National Ranking
8478

Ingrid A. Mayer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ingrid A. Mayer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 563 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ingrid A. Mayer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ingrid A. Mayer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ingrid A. Mayer is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on Oncology and related subfields including Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Genetics.

Their main research topics cover a range of areas within cancer study and treatment. These include Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, and Cancer Risks and Factors.

Frequent publication venues for their work include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • Breast Cancer Research and Treatment

Some of the recent papers associated with their research are:

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology (2020), Journal of the National Comprehensive Cancer Network
  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1 (2020), Annals of Oncology
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021 (2021), Journal of the National Comprehensive Cancer Network
  • Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab (2021), Cancer Discovery
  • Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021), Journal of Clinical Oncology

They frequently collaborate with other researchers in oncology and cancer research. Notable co-authors include:

  • Hope S. Rugo
  • Vandana G. Abramson
  • Lynne I. Wagner
  • Carlos L. Arteaga
  • Sibylle Loibl

Best Publications

  • Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    Giampaolo Bianchini;Justin M. Balko;Ingrid A. Mayer;Melinda E. Sanders

  • Clinical practice guidelines in oncology

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    William J. Gradishar;Benjamin O. Anderson;Jame Abraham;Rebecca Aft

  • The PI3K/AKT Pathway as a Target for Cancer Treatment.

    Ingrid A. Mayer;Carlos L. Arteaga

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Breast cancer: Clinical practice guidelines in oncology

    Robert W. Carlson;Benjamin O. Anderson;Harold J. Burstein;Charles E. Cox

  • Resistance to Trastuzumab in Breast Cancer

    Paula R. Pohlmann;Ingrid A. Mayer;Ray Mernaugh

  • NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

    Joseph A. Sparano;Robert J. Gray;Peter M. Ravdin;Della F. Makower;Della F. Makower

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Catherine Van Poznak;Mark R. Somerfield;Robert C. Bast;Massimo Cristofanilli

  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    F. André;E.M. Ciruelos;D. Juric;S. Loibl

  • Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results

    Thomas E. Yankeelov;Martin Lepage;Martin Lepage;Anuradha Chakravarthy;Elizabeth E. Broome

  • Invasive breast cancer version 1.2016

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.

    Angel Guerrero-Zotano;Ingrid A. Mayer;Carlos L. Arteaga

Frequent Co-Authors

Carlos L. Arteaga
Carlos L. Arteaga The University of Texas Southwestern Medical Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Justin M. Balko
Justin M. Balko Vanderbilt University Medical Center
Aditya Bardia
Aditya Bardia Harvard University
Eric P. Winer
Eric P. Winer Yale University
Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Timothy J. Whelan
Timothy J. Whelan McMaster University
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
Ian E. Krop
Ian E. Krop Harvard University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Medicine doesn’t always follow a single traditional path. Numerous related online degree programs and career options can help you advance or specialize in healthcare. For instance, if you’re a registered nurse seeking to become a Family Nurse Practitioner, asn to fnp programs offer flexible online bridge options. These programs are designed to help you progress efficiently from an ASN to an MSN and move into advanced practice roles.

Broader healthcare roles are also accessible online. For those interested in hospital or healthcare management, cahme accredited mha online programs provide quality training in administration, opening doors to leadership careers in the medical field.

Allied health careers like nutrition are in high demand. If you’re passionate about wellness and nutrition, a nutritionist online degree can be the first step to becoming a certified nutrition specialist or consultant, all from the convenience of your home.

Nurses seeking to upgrade qualifications should also explore rn to bsn online no clinicals programs, which offer even more flexible advancement for working professionals without the need for additional clinical hours. These diverse online choices make healthcare career growth more accessible than ever.

Best Scientists Citing Ingrid A. Mayer

Trending Scientists

Recently Published Articles